CurrentUnitedHealthcarePolicy CSNC-MP-02.05

Chemo Observation Inpatient Hospitalization Nc Cs

State-specific UnitedHealthcare medical policy for North Carolina defining when chemotherapy administration requires facility observation or inpatient hospitalization versus outpatient/office/home administration; excludes individuals under 18 years of age.

Policy Summary

PayerUnitedHealthcare

PolicyChemo Observation Inpatient Hospitalization Nc Cs

Policy CodePolicy CSNC-MP-02.05

Change TypeSupporting information & template updatesstate-specific version created

Effective DateApr 1, 2025

Next Review Date

Key ActionA written protocol must be followed by the provider administering the chemotherapy drug.

SourceLink

POLICY UPDATE CHANGES

Created state-specific policy version for the state of North Carolina.

Template update removed content/language pertaining to Mississippi.

Supporting Information updated: Clinical Evidence and References; previous policy archived (CS198.H).

>=1Regimens explicitly listed as requiring inpatient monitoring

3Clinical conditions requiring inpatient stay (listed)

3Conditions potentially requiring observation stay (listed)

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

This is the state-specific UnitedHealthcare medical policy CSNC-MP-02.05 for North Carolina that defines when chemotherapy administration requires facility observation or inpatient hospitalization versus outpatient/office/home administration. The policy takes a mixed coverage stance: most chemotherapies can be given outpatient or at home, but certain regimens, administration complexities, or clinical conditions necessitate observation or inpatient care. The policy explicitly excludes individuals under 18 years of age.

Key clinical thresholds

Coordination duration for multiple infusionsOver 96 hours (e.g., EPOCH/DA-EPOCH/R-EPOCH, ESHAP/ R-ESHAP, Hyper-CVAD when coordination of multiple infusions or multiple drugs over 96 hours is required)

Interleukin-2 dosingInterleukin-2 600,000 IU/kg IV every 8 hours for up to 14 consecutive doses over 5 days

Ifosfamide high-dose threshold> 1 g/m2/day (Ifosfamide infusion > 1 g/m2/day requires inpatient monitoring for sarcoma when close electrolyte/urine pH monitoring or alkalinization is needed)

High-dose methotrexate threshold> 500 mg/m2 (methotrexate dose > 500 mg/m2 with methotrexate-level–guided management requires inpatient monitoring)

Leucovorin rescue dosingLeucovorin 15 mg every 6 hours for eight doses beginning 12 hours after completion; increase to 50 mg IV every 6 hours if methotrexate levels >20 µmol/L at 0h, >1.0 µmol/L at 24h, or >0.1 µmol/L at 48h until levels <0.1 µmol/L

When Inpatient or Observation Stay Is Medically Necessary

General applicability

This policy applies to members in North Carolina and excludes individuals under 18 years of age.

Location and age: Member is located in the state of North Carolina
Location and age: Member is 18 years of age or older

Policy metadata: Policy Number: CSNC-MP-02.05; Effective Date: April 1, 2025

State-specific version created 11/01/2025; template and references updated per policy history.

Inpatient hospitalization is medically necessary when ALL of the following apply for specified regimens/conditions

Inpatient stay is medically necessary for certain regimens that require complex multi-day administration/monitoring or for specified clinical conditions/complications.

Specific chemotherapy regimens requiring inpatient stay

EPOCH/DA-EPOCH/R-EPOCH: EPOCH, DA-EPOCH, or R-EPOCH for lymphoma when coordination of multiple infusions or multiple drugs over 96 hours is requiredover 96 hours
ESHAP/R-ESHAP: ESHAP or R-ESHAP for lymphoma when coordination of multiple infusions or multiple drugs over 96 hours is required or when monitoring for CNS toxicity with cytarabine is neededover 96 hours
Monitor for CNS toxicity with cytarabine
Interleukin-2 infusion (600,000 IU/kg IV every 8 hours for up to 14 consecutive doses over 5 days) for melanoma or renal cell cancer when continuous cardiac monitoring, close monitoring of serum electrolytes/creatinine/bilirubin/urine output, vasopressor support (dopamine), or proximity to ICU is required600,000 IU/kg IV every 8 hours for up to 14 doses over 5 days

Observation stay may be appropriate

The following clinical conditions or complications may require an observation stay rather than inpatient admission.

Conditions appropriate for observation stay

Known hypersensitivity reactions from previous infusion
May be managed with observation rather than inpatient admission depending on severity
High-volume fluid needs: Congestive heart failure or chronic renal failure requiring high volume fluid infusions
Observation may be appropriate to monitor fluid balance
TACE/intra-arterial: Transcatheter Arterial Chemoembolization (TACE) or intra-arterial chemotherapy infusion

Observation vs inpatient guidance:

Case-by-case review

Conditions not specifically listed will be reviewed on a case-by-case basis using InterQual level-of-care criteria.

Case-by-case review: Will be reviewed on a case-by-case basis using InterQual LOC: Acute Adult, Hematology/Oncology: Complications or Disease Progression and/or InterQual LOC: Acute Adult Hematology/Oncology: Treatments

Use InterQual criteria to determine medical necessity for observation or inpatient care

Provider Actions & Requirements

Documentation Required

Written protocol required

A written protocol must be followed by the provider administering the chemotherapy drug.

Prior Authorization

Extension of inpatient stay requires clinical review

Any requests for extension of the inpatient stay beyond the recommended day(s) must be clinically reviewed.

Documentation Required

Use InterQual for case-by-case reviews

For cases not specifically listed, refer to InterQual LOC: Acute Adult, Hematology/Oncology: Complications or Disease Progression and/or InterQual LOC: Acute Adult Hematology/Oncology: Treatments for medical necessity case-by-case reviews.

Background, Evidence, and Definitions

Most chemotherapies can be administered in outpatient clinics, physician offices, or at home, but some regimens require complex, multi-day continuous infusions or close physiologic monitoring that typically necessitate an observation unit or inpatient admission (examples include prolonged continuous-infusion regimens and high‑dose cytotoxics). For cases not expressly listed, the policy directs reviewers to use InterQual criteria (InterQual LOC: Acute Adult, Hematology/Oncology: Complications or Disease Progression and/or InterQual LOC: Acute Adult Hematology/Oncology: Treatments) for case‑by‑case determinations.

Citation	Study summary
Tirtei et al. (2024)	Retrospective multicenter cohort (n=26) assessing prolonged 14-day high-dose ifosfamide in outpatient setting for recurrent/refractory osteosarcoma; reported manageable toxicity, no permanent discontinuations for adverse events, some dose reductions/delays; limited by small sample size.
Nelles et al. (2023)	Retrospective cohort (n=13) of DA-EPOCH-R in double-hit lymphoma delivered primarily outpatient; CR 69%, median EFS 61 months and OS 64 months; admissions occurred as needed for complications (eg, febrile neutropenia); limited by small sample size.
Banh et al. (2021)	Single-center retrospective cohort (n=86; 57 outpatient, 29 inpatient) comparing outpatient vs inpatient ifosfamide therapy; higher rates of grade 4 cytopenias in inpatient group; outpatient administration associated with fewer hospital days and lower cost but study limited by single center and possible selection bias.
Li et al. (2020)	Single-center review (n=56) of DA-EPOCH outpatient administration (193 of 219 cycles outpatient); no hospitalizations during outpatient administration, resulting in saved hospital days; hospitalizations occurred between cycles (eg, neutropenic fever); limited by lack of concurrent comparison group.

TACE (Transcatheter Arterial Chemoembolization): procedure in which the blood supply to a tumor is blocked after anticancer drugs are given in blood vessels near the tumor.

OpenPayer

Chemo Observation Inpatient Hospitalization Nc Cs

Coverage Summary

When Inpatient or Observation Stay Is Medically Necessary

Provider Actions & Requirements

Policy Identifier & Codes

Background, Evidence, and Definitions

Revision History